Key facts
- Immunethep’s last known valuation is $3.6M (Oct 2018).
- It has raised $2.9M; the latest was Later Stage VC ($2.0M) in Feb 2025.
- Notable investors include European Innovation Council, European Commission, Gates Foundation, Venture Catalysts, CARB-X — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Immunethep
- ·The full record, as it builds
Funding rounds
No funding rounds for Immunethep are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immunethep
Developer of a biotechnology company intended to develop bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. The company offers therapies, including the development of neonatal vaccines to protect neonates from bacterial infections inside the mother's womb, enabling patients to develop their immunity and prevent multi-bacterial infections and diseases through advanced healthcare methods.
- Sector
- Healthcare
- HQ
- Cantanhede, Portugal
- Founded
- 2013
- Employees
- 22
- Website
- immunethep.com/
- Ownership
- Privately Held (backing)
Immunethep doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunethep shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunethep in its N-PORT filings yet. We sweep new filings monthly.